Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer and autoimmune diseases. Founded in 2014 and spun-out from University College London, Autolus has rapidly grown its capabilities and resources to manufacture, develop, and commercialize its innovative CAR T-cell product candidates. The company focuses on developing precise, controlled, and highly active therapies by leveraging its expertise in advanced cell programming and T-cell manufacturing.

Autolus has a robust pipeline of products in both preclinical and clinical development, with a focus on hematological malignancies and solid tumors. The company's lead product candidate, obe-cel, has demonstrated promising results in clinical trials for adult acute lymphoblastic leukemia (ALL) and is currently being investigated for other indications. Autolus is committed to its mission of providing life-changing treatments for patients with cancer and autoimmune diseases through its innovative approach and dedication to research and development.

Autolus Therapeutics has adopted a hybrid working arrangement, allowing employees to work flexibly where their role permits. This approach prioritizes employee well-being and enhances business functionality and productivity.

Autolus offers a competitive benefits package to its employees, including medical coverage, employee assistance programs (EAPs), and retirement savings plans. The company also promotes a flexible and dynamic working environment that fosters creativity, leadership, and teamwork.

Autolus Therapeutics is a biotechnology company dedicated to developing and commercializing innovative CAR T cell therapies, aiming to deliver life-changing benefits to patients with cancer and autoimmune diseases. Their mission is rooted in pushing the boundaries of cancer therapy through advanced cell programming technologies and manufacturing processes, with a focus on creating best-in-class treatments that offer significant advantages over current standard care.

Autolus Therapeutics promotes a collaborative, diverse, and dynamic work environment that values creativity, leadership, and teamwork. The company emphasizes flexibility, employee well-being, and a strong sense of community. They actively promote learning and development opportunities, offer competitive benefits, and support hybrid working arrangements. Their culture encourages a shared commitment to pushing the boundaries of cancer therapy and delivering life-changing treatments to patients.

Autolus Therapeutics prioritizes diversity, equity, and inclusion, believing all voices are valuable and must be heard. They actively promote a workplace that creates a sense of belonging for everyone, fostering a culture that draws on the differences in experience and work styles of its employees. This commitment to diversity and inclusion is a fundamental part of their operations, and they are dedicated to improving representation within their business and the industry as a whole.